Laia Rosich - Concepedia

Author

Laia Rosich

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Also Known As

L Rosich, Laia Rosich, Rosich Laia

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Universitat de Barcelona Hospital Clínic de Barcelona Centro de Investigación Biomédica en Red de Cáncer Anaxomics (Spain)

About

Laia Rosich is an author at Consorci Institut D'Investigacions Biomediques August Pi I Sunyer specializing in immunology, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	142
2	Cell Biology	4	4	142
3	Immunology	4	4	142
4	Pathology	1	1	35
5	Autoimmune Disease	1	1	26

Laia Rosich

Publications

751

Citations

H-Index

Page 1

	Year	Citations
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Gaël Roué, Patricia Pérez‐Galán, Mònica López‐Guerra, Blood	2010	108
Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters Sílvia Xargay‐Torrent, Mònica López‐Guerra, Ifigènia Saborit-Villarroya, Clinical Cancer Research	2011	78
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells Mònica López‐Guerra, Sílvia Xargay‐Torrent, Laia Rosich, Leukemia Signal TransductionSignaling PathwayNotch1-mutated Cll CellsMedicineImmunology	2014	69
Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma Laia Rosich, Sílvia Xargay‐Torrent, Mònica López‐Guerra, Clinical Cancer Research	2012	68
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia Sílvia Xargay‐Torrent, Mònica López‐Guerra, Laia Rosich, Oncotarget	2015	66
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia Neus Giménez, Alejandra Martínez‐Trillos, Arnau Montraveta, Haematologica	2018	59
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia Neus Giménez, Ralph Schulz, Morihiro Higashi, Leukemia	2019	46
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia Arnau Montraveta, Eriong Lee‐Vergés, Jocabed Roldán, Oncotarget Chronic Lymphocytic LeukemiaImmunologyPathologyBendamustine ResponseImmunotherapy	2015	35
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma Laia Rosich, Arnau Montraveta, Sílvia Xargay‐Torrent, Oncotarget	2014	34
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells Mònica López‐Guerra, Sílvia Xargay‐Torrent, Patricia Fuentes, Oncogene	2019	33

Page 1